Bonstein Sara 4

Accession 0001628280-25-035755

CIK 0001104506other

Filed

Jul 22, 8:00 PM ET

Accepted

Jul 23, 4:35 PM ET

Size

21.4 KB

Accession

0001628280-25-035755

Form 4

Period: 2025-07-21

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2025-07-21$29.13/sh+15,890$462,876→ 114,805 total
Sale
Common Stock
2025-07-21$102.38/sh−32,090$3,285,374→ 99,815 total
Exercise/Conversion
Stock Option (right to buy)
2025-07-21−3,443→ 8,580 total
Exercise: $26.46Exp: 2031-05-12→ Common Stock (3,443 underlying)
Exercise/Conversion
Common Stock
2025-07-21$26.46/sh+3,443$91,102→ 87,460 total
Exercise/Conversion
Stock Option (right to buy)
2025-07-21−15,890→ 47,670 total
Exercise: $29.13Exp: 2034-01-04→ Common Stock (15,890 underlying)
Exercise/Conversion
Common Stock
2025-07-21$28.88/sh+11,455$330,820→ 98,915 total
Exercise/Conversion
Common Stock
2025-07-21$34.03/sh+17,100$581,913→ 131,905 total
Sale
Common Stock
2025-07-21$103.03/sh−26,310$2,710,719→ 73,505 total
Exercise/Conversion
Stock Option (right to buy)
2025-07-21−11,455→ 0 total
Exercise: $28.88Exp: 2030-02-03→ Common Stock (11,455 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-07-21−17,100→ 0 total
Exercise: $34.03Exp: 2031-01-07→ Common Stock (17,100 underlying)

Footnotes (5)

[F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
[F2]This is the weighted average sales price representing 32,090 shares sold at prices ranging from $101.77 to $102.76 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
[F3]This is the weighted average sales price representing 26,310 shares sold at prices ranging from $102.77 to $103.37 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
[F4]The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
[F5]The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Documents

1 file

INSMED Inc

CIK 0001104506

Entity typeother